Additionally, we find that the impact of CD19 loss is significantly more dramatic in spleen versus bone marrow, and the loss of IFNγR potently sensitizes splenic B-ALL cells to CAR-T therapy but is much less potent as a sensitizer in bone marrow tumor cells. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.